GILUPI Will Attend At The ACTC Congress In Rhodos
Potsdam, 21.09.2017 (PresseBox) - GILUPI GmbH is pleased to announce its participation at the 2017 ACTC (Advances in Circulating Tumor Cells) congress.
The 3rd ACTC meeting will take place from 4th to 7th October in Rhodos, Greece and is focused on “Liquid Biopsy in clinical practice”. This congress brings together researchers, clinicians and companies, to discuss practical implementation of CTCs (circulating tumor cells) and ctDNA (circulating tumor DNA) and translate much of the excellent basic research in this field into clinical practice.
GILUPI will use this opportunity to present interim data from a clinical trial at the SRH Wald-Klinikum Gera - a certified lung cancer center in Germany. The clinical investors Dr. med. habil. Thomas Lesser and Dr. med. Julia Herrmann using the GILUPI CellCollector®, to monitor CTC counts before and after surgery in non-small cell lung cancer (NSCLC) patients. First results from 20 patients show that CTCs were isolated independent from cancer grade and could even be detected in quite early tumor stages. The difference between CTC occurrence before and after surgery suggested the possibility to identify patients responding to therapy or patients with stable disease. Moreover, a correlation between CTC numbers and clinical lack of recurrence was observed. In addition, patients were tested positive for PD L1 (Programmed death-ligand 1 / CD274) expression in CTCs.
The poster presentation will take place on Thursday 5th of October at 3.30 pm - 4.30 pm. You are invited to meet Dr. Johanna Schiller from the GILUPI R&D department.
The 3rd ACTC meeting will take place from 4th to 7th October in Rhodos, Greece and is focused on “Liquid Biopsy in clinical practice”. This congress brings together researchers, clinicians and companies, to discuss practical implementation of CTCs (circulating tumor cells) and ctDNA (circulating tumor DNA) and translate much of the excellent basic research in this field into clinical practice.
GILUPI will use this opportunity to present interim data from a clinical trial at the SRH Wald-Klinikum Gera - a certified lung cancer center in Germany. The clinical investors Dr. med. habil. Thomas Lesser and Dr. med. Julia Herrmann using the GILUPI CellCollector®, to monitor CTC counts before and after surgery in non-small cell lung cancer (NSCLC) patients. First results from 20 patients show that CTCs were isolated independent from cancer grade and could even be detected in quite early tumor stages. The difference between CTC occurrence before and after surgery suggested the possibility to identify patients responding to therapy or patients with stable disease. Moreover, a correlation between CTC numbers and clinical lack of recurrence was observed. In addition, patients were tested positive for PD L1 (Programmed death-ligand 1 / CD274) expression in CTCs.
The poster presentation will take place on Thursday 5th of October at 3.30 pm - 4.30 pm. You are invited to meet Dr. Johanna Schiller from the GILUPI R&D department.